New to peptides? Start with the foundations ->
Why people use Retatrutide for weight loss
Beyond Tirzepatide. Will Retatrutide be the next-level weight loss drug? The short answer: yes, this is one of the more-discussed uses for Retatrutide - but the evidence quality and the right protocol depend on what you're actually trying to fix.
This page covers what's known, what's not, and what the editorial take is for normal humans considering Retatrutide for weight loss.
What the evidence says
Evidence tier: RCT (late-stage). Late-stage human trials are reporting; FDA review pending. Real evidence, near-final.
- Phase-2 trial (TRIUMPH-1, NEJM 2023) showed 24.2% body weight loss at 48 weeks on the highest dose - higher than any other weight-loss drug ever published.
- Triple-agonist: hits GLP-1, GIP, and glucagon receptors (one more than Tirzepatide's two).
- FDA submission expected 2026-2027. Not yet available outside trials and compounding.
Protocol notes
Once-weekly subcutaneous injection. Dose-finding trials used 1mg-12mg weekly. Compounded versions exist before approval.
Always with a sports-medicine doctor, telehealth provider, or specialist sign-off. Self-experimenting on injection schedules without clinical input is the most common way people waste money and get hurt.
What to skip
- Vendors without a Certificate of Analysis (COA). Random gym-bro vendors with no third-party testing. The peptide market has a quality-control problem; the answer is COA per peptide, every time.
- Pre-mixed blends from non-pharmacy sources. Compounding pharmacies that produce pre-mixed combinations with COAs are fine. Random vendor "stack vials" are not.
- Massively over-dosed protocols. More is rarely better with peptides. Receptor saturation is real. Stick to evidence-based dosing.
Where to go next
- Full Retatrutide directory entry - status, sourcing, studies, what to skip
- What are peptides - if you skipped the foundation
- How peptides actually work - mechanism in plain English
- The Tier List - which ones to take seriously
- Subscribe to the dispatch
Subscribe to the dispatch
The weekly Protocol One dispatch covers what's moving in peptides, GLP-1s, and longevity protocols. Free. 5-min read. Broken down for normal humans.
Last reviewed · 2026-05-07 · Page generated by Protocol One matrix engine